CAMBRIDGE, MA–Eisai Co. announced that it has decided to establish a research facility in Cambridge, MA.
The company said in a statement that the Eisai Center for Genetics Guided Dementia Discovery (G2D2) will focus on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia.
G2D2 is scheduled to commence operation in the first quarter of fiscal 2019, and the head of the new research facility will be Nadeem Sarwar, Ph.D., the current President of Andover innovative Medicines (AiM) Institute, which is also located in Massachusetts. Once G2D2 commences operation, the current AiM Institute will be closed down.
G2D2 will be established within the Alewife Research Center in the Alewife area, located in the north-west part of Cambridge, which is one of the world’s leading biotechnology clusters where private research organizations in addition to academic institutions such as Harvard University, the Massachusetts Institute of Technology and Tufts University are concentrated.
Leveraging the benefits of the location, a research space that can be used by external organizations will be set up at G2D2 to enhance collaboration with outstanding researchers and open innovation initiatives to promote immuno-dementia drug discovery.